CEO Matthew Angel Reports 35.9% Stake in Tempest Therapeutics Following Asset Acquisition
Summary
Matthew Angel, CEO, President, and Director of Tempest Therapeutics, has reported beneficial ownership of 35.9% of the company's common stock following the recent asset acquisition, solidifying his significant stake and control.
Key Events
-
Significant Ownership Stake
Matthew Angel, CEO, President, and Director, now beneficially owns 4,837,070 shares, representing 35.9% of Tempest Therapeutics' outstanding common stock.
-
Acquisition-Related Ownership
This ownership stems from the asset purchase agreement with Erigen LLC and Factor Bioscience Inc., which closed on February 3, 2026, where Tempest issued 8,268,495 shares as consideration. Angel acquired his interest through personal funds invested in Erigen.
-
Lock-Up Agreement in Place
Erigen, the entity through which Angel received shares, entered into a lock-up agreement restricting the transfer of 50% of its shares for 180 days post-closing.
-
Investment Purpose Stated
Angel states the shares were acquired for investment purposes, with potential for future acquisitions or dispositions.
Analysis
This Schedule 13D filing formally discloses that Matthew Angel, the CEO, President, and a Director of Tempest Therapeutics, has become a significant beneficial owner, holding 35.9% of the company's common stock. This substantial stake, valued at over $11.7 million, is a direct result of the asset acquisition from Erigen LLC and Factor Bioscience Inc., which was previously disclosed in 8-K filings on January 28, 2026, and February 6, 2026. While the overall asset acquisition was highly dilutive, Angel's personal investment and subsequent large ownership position demonstrate a strong alignment of interests with shareholders and a significant vote of confidence in the company's future direction. His role as a major shareholder, combined with his executive positions, indicates consolidated control and a clear strategic vision following the recent corporate restructuring. Investors should monitor future disclosures regarding the integration of the acquired assets and any strategic initiatives under this new ownership structure.
At the time of this filing, TPST was trading at $2.42 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $32.6M. The 52-week trading range was $2.17 to $12.48. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.